Company initially withdrew a marketing authorisation application for the gene therapy last year
News
ABPI launches updated Code of Practice
The new Code has been updated to reflect changes in the pharma environment
‘Mix and match’ COVID-19 vaccine study yields promising results
Mixing different vaccines produces a strong immune response against virus, according to researchers
CHMP recommends approval of UCB’s Bimzelx for plaque psoriasis
Bimzelx inhibits IL-17A and IL-17F, two key cytokines that drive inflammatory processes
Lilly’s tirzepatide beats Ozempic in head-to-head type 2 diabetes trial
All three doses of Lilly’s drug demonstrated superior HbA1C and body weight reductions compared to Ozempic
AZ doses first participants with COVID-19 variant vaccine
The vaccine has been designed with minor genetic alterations to the spike protein based on the beta (B.1.351) variant
BMS’ CAR T therapy Abecma moves closer toward EU approval
Positive CHMP opinion is based on results from the pivotal Phase II KarMMa study
Scientists identify link between genetic changes and rare childhood cancer rhabdomyosarcoma
Genetic changes could be used to guide treatment for the rare and aggressive cancer type
Over two million people may have had long COVID in England
Study of self-reported data found a sizeable portion of individuals reporting persistent COVID-19 symptoms
Blood test can detect more than 50 types of cancer
Findings of the latest study assessing the test back its use as a screening tool, researchers say
Sanofi, Regeneron’s Libtayo cleared for basal cell carcinoma
Libtayo is the first immunotherapy indicated for patients with advanced basal cell carcinoma
PharmaTimes announce partnership for the Communications Awards Charity Challenge
PharmaTimes are proud to confirm that we will be partnering with the Meningitis Research Foundation for the 2021 Communications Awards Charity Challenge.
‘What’s next for patient advocacy?’ Senior leader speakers for Patient Partnership Index event announced
‘What’s next for patient advocacy?’ will take place on Tuesday 6th July at 8.30am
Novartis announces digital collaboration with Hewlett Packard Enterprise
Collaboration aims to accelerate Novartis’ use of data and digital technologies
Lecanemab wins breakthrough therapy designation in Alzheimer’s disease
Designation is based on data from a Phase IIb study including 856 patients with mild Alzheimer’s disease
